Ultragenyx Pharmaceutical RARE US And Canada — Royalty Agreement Termination Threshold Amount

Similar metrics at other companies

INVANon Us — Percentage Of Maximum Royalty Based On Achievement Of Annual Net Product Sales Thresholds

1.9%—

INVANon Us — Percentage Of Minimum Royalty Rate

1.1%—

BMYNorth America — Royalty rate due to regulatory approvals

1%0.0pp

INVANon Us — Percentage Of Royalty Payable On Net Sales

7.5%—

BCRXRoyalty revenues payable

-$31.48M-19.6%

RBLXUnited States and Canada — Revenue

$838M+29.5%

Questions, answered.

What is Ultragenyx Pharmaceutical's US and canada — royalty agreement termination threshold amount?

Ultragenyx Pharmaceutical (RARE) reported US and canada — royalty agreement termination threshold amount of $725M in Q1 2026.

What does US and canada — royalty agreement termination threshold amount mean?

This metric identifies the specific financial milestone or cumulative revenue threshold that, once reached, triggers the termination or modification of royalty payment obligations to a third party. It serves as a critical indicator of when the company transitions to retaining a larger share of product economics. Investors use this to forecast long-term margin expansion potential as royalty burdens expire.